- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.09. | Orchestra BioMed executive acquires shares worth over $47k | 1 | Investing.com | ||
| 11.09. | Orchestra BioMed executive sells over $73k in company stock | 2 | Investing.com | ||
| 11.09. | Orchestra BioMed director sells over $30k in company shares | 4 | Investing.com | ||
| 07.09. | Orchestra BioMed executive sells over $120k in company stock | 2 | Investing.com | ||
| 13.08. | Orchestra BioMed reports Q2 results | 1 | Seeking Alpha | ||
| 12.08. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update | 95 | GlobeNewswire (Europe) | NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies... ► Artikel lesen | |
| 12.08. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.06. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 11.06. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Participate in Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 15.05. | Orchestra BioMed reports Q1 results | 1 | Seeking Alpha | ||
| 13.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update | 906 | GlobeNewswire (Europe) | Company hosting in-person R&D day event, focused on atrioventricular interval modulation ("AVIM") therapy, including the unmet need in hypertension, mechanism of action, clinical results and design... ► Artikel lesen | |
| 13.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents | 2 | GlobeNewswire (USA) | ||
| 27.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update | 123 | GlobeNewswire (Europe) | Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with... ► Artikel lesen | |
| 06.02. | PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit | 503 | Newsfile | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds" or the "Company"), a clinical-stage neuroscience company dedicated to the development... ► Artikel lesen | |
| 08.01. | Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients | 233 | GlobeNewswire (Europe) | Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be... ► Artikel lesen | |
| 13.11.23 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update | 235 | GlobeNewswire (Europe) | U.S. FDA granted Investigational Device Exemption ("IDE") approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patientsBACKBEAT pivotal... ► Artikel lesen | |
| 24.10.23 | OBiO Technology (Shanghai) Corp., Ltd.: OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product | 603 | PR Newswire | Visit OBiO at ESGCT 30th Annual Congress in Brussels
SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,610 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,430 | +1,90 % | Revolution in der Krebsbehandlung: Wie die Plattform von Defence Therapeutics die Wirksamkeit von Medikamenten verbessert und Krebszellen präzise bekämpft | Defence Therapeutics (WKN: A3CN14 | ISIN: CA24463V1013 | Ticker-Symbol: DTC) ist ein börsennotiertes Biotechnologieunternehmen, das Pionierarbeit leistet und sich auf die Entwicklung der nächsten Generation... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,600 | -1,94 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,540 | 0,00 % | Insider-Verkauf bei Recursion Pharmaceuticals: Direktor veräußert Aktien im Wert von 76.326 US-Dollar | ||
| BEAM THERAPEUTICS | 24,370 | -8,61 % | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results | U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,100 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ASSERTIO | 1,150 | +1,77 % | Assertio Holdings, Inc.: Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 | ||
| ARCTURUS THERAPEUTICS | 20,600 | 0,00 % | Pad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock | ||
| SIGA TECHNOLOGIES | 7,080 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,135 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 7,725 | -1,84 % | Vir Biotechnology präsentiert Ergebnisse der Hepatitis-Studie | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,450 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30... ► Artikel lesen | |
| ARVINAS | 27,050 | 0,00 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen | |
| BIO-PATH | 1,080 | -6,90 % | BIO-PATH HOLDINGS, INC. - 8-K, Current Report |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,400 Euro und damit -4,59 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.
